Multiple sclerosis:: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β

被引:77
作者
Özenci, V [1 ]
Kouwenhoven, M [1 ]
Teleshova, N [1 ]
Pashenkov, M [1 ]
Fredrikson, S [1 ]
Link, H [1 ]
机构
[1] Huddinge Univ Hosp, Karolinska Inst, Unit Neuroimmunol, Div Neurol, S-14186 Huddinge, Sweden
关键词
multiple sclerosis; cytokines; ELISPOT; interferon-beta; metalloproteinases;
D O I
10.1016/S0165-5728(00)00281-2
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Interferon-beta (IFN-beta) has a beneficial influence on the course of multiple sclerosis (MS) and has become standard treatment of this disease, though its mechanisms of action are incompletely understood. This study examines the effect of IFN-beta treatment on the cytokines IL-6, TNF-alpha, IFN-gamma and IL-10; the metalloproteinases MMP-3, -7 and -9 and the tissue inhibitor of metalloproteinase-1 (TIMP-1). IFN-beta treatment resulted in decreased numbers of mononuclear cells (MNC) secreting IL-6 and TNF-alpha and expressing mRNA of MMP-3 and MMP-9 compared to pretreatment levels. On the contrary, numbers of IL-10 secreting MNC and TIMP-1 mRNA expressing were augmented during IFN-beta therapy. Whether the down-regulatory effects on pro-inflammatory and upregulatory effects on anti inflammatory molecules are a direct result of IFN-beta on the immune system or secondary to clinical stabilization of MS pathology induced by IFN-beta remains to be evaluated. (C) 2000 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:236 / 243
页数:8
相关论文
共 27 条
[1]   Measurement of serum cytokines [J].
Barnes, A .
LANCET, 1998, 352 (9124) :324-325
[2]   IFN-beta(1b) treatment of relapsing multiple sclerosis has no effect on CD3-induced inflammatory or counterregulatory anti-inflammatory cytokine secretion ex vivo after nine months [J].
Brod, SA ;
Nelson, LD ;
Khan, M ;
Wolinsky, JS .
INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1997, 90 (1-2) :135-144
[3]   Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: An overview [J].
Chandler, S ;
Miller, KM ;
Clements, JM ;
Lury, J ;
Corkill, D ;
Anthony, DCC ;
Adams, SE ;
Gearing, AJH .
JOURNAL OF NEUROIMMUNOLOGY, 1997, 72 (02) :155-161
[4]   REVERSE ELISPOT ASSAY FOR CLONAL ANALYSIS OF CYTOKINE PRODUCTION .1. ENUMERATION OF GAMMA-INTERFERON-SECRETING CELLS [J].
CZERKINSKY, C ;
ANDERSSON, G ;
EKRE, HP ;
NILSSON, LA ;
KLARESKOG, L ;
OUCHTERLONY, O .
JOURNAL OF IMMUNOLOGICAL METHODS, 1988, 110 (01) :29-36
[5]  
DECLERCK YA, 1989, J BIOL CHEM, V264, P17445
[6]   The effect of interferon beta-1 beta on lymphocyte endothelial cell adhesion [J].
DhibJalbut, S ;
Jiang, H ;
Williams, GJ .
JOURNAL OF NEUROIMMUNOLOGY, 1996, 71 (1-2) :215-222
[7]   THE MATRIX METALLOPROTEINASES AND THEIR NATURAL INHIBITORS - PROSPECTS FOR TREATING DEGENERATIVE TISSUE-DISEASES [J].
DOCHERTY, AJP ;
OCONNELL, J ;
CRABBE, T ;
ANGAL, S ;
MURPHY, G .
TRENDS IN BIOTECHNOLOGY, 1992, 10 (06) :200-207
[8]   Changes in plasma cytokines induced by interferon-β1a treatment in patients with multiple sclerosis [J].
Duddy, ME ;
Armstrong, MA ;
Crockard, AD ;
Hawkins, SA .
JOURNAL OF NEUROIMMUNOLOGY, 1999, 101 (01) :98-109
[9]  
DUQUETTE P, 1995, NEUROLOGY, V45, P1277
[10]   Intramuscular interferon beta-1 alpha for disease progression in relapsing multiple sclerosis [J].
Jacobs, LD ;
Cookfair, DL ;
Rudick, RA ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Granger, CV ;
Simon, JH ;
Alam, JJ ;
Bartoszak, DM ;
Bourdette, DN ;
Braiman, J ;
Brownscheidle, CM ;
Coats, ME ;
Cohan, SL ;
Dougherty, DS ;
Kinkel, RP ;
Mass, MK ;
Munschauer, FE ;
Priore, RL ;
Pullicino, PM ;
Scherokman, BJ ;
WeinstockGuttman, B ;
Whitman, RH ;
Baird, WC ;
Fillmore, M ;
Bona, LM ;
ColonRuiz, ME ;
Nadine, BS ;
Donovan, A ;
Bennett, S ;
Kieffer, YM ;
Umhauer, MA ;
Miller, CE ;
Kilic, AK ;
Sargent, EL ;
Schachter, M ;
Shucard, DW ;
Weider, V ;
Catalano, BA ;
Cervi, JM ;
Czekay, C ;
Farrell, JL ;
Filippini, JS ;
Matyas, RC ;
Michienzi, KE ;
Ito, M ;
OMalley, JA .
ANNALS OF NEUROLOGY, 1996, 39 (03) :285-294